Taking a new approach to tackle neurodegenerative diseases
Drug Discovery World
OCTOBER 4, 2022
Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . Erhardt adds that despite the ever-increasing number of people with AD, there has been an erosion of market value (from $4.2
52 
Let's personalize your content